caa a22 4500 465789331 CHVBK 20180323112018.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00216934 doi (NATIONALLICENCE)springer-10.1007/BF00216934 Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck [Elektronische Daten] [Douglas Mattox, Daniel Von Hoff, Stanley Balcerzak] Summary: Eighteen patients are evaluable for response in a Phase II trial of Mitoxantrone for advanced adenoid cystic carcinoma of the head and neck. One patient had a complete response; there were no partial responses. Twelve patients had stable disease for 3 or more months. There was no significant anti-tumor activity of Mitoxantrone in the group of patients with adenoid cystic carcinoma, all of whom were previously heavily treated with surgery, chemotherapy and/or radiation therapy. Kluwer Academic Publishers, 1990 mitoxantrone nationallicence adenoid cystic carcinoma nationallicence dihydroxyanthracenedione nationallicence Mattox Douglas Johns Hopkins Hospital, Baltimore, MD aut Von Hoff Daniel University of Texas Health Science Center at San Antonio, San Antonio, TX aut Balcerzak Stanley Ohio State University Hospital, Columbus, OH, USA aut Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 105-107 0167-6997 8:1<105 1990 8 10637 https://doi.org/10.1007/BF00216934 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00216934 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mattox Douglas Johns Hopkins Hospital, Baltimore, MD aut NATIONALLICENCE 700 1- Von Hoff Daniel University of Texas Health Science Center at San Antonio, San Antonio, TX aut NATIONALLICENCE 700 1- Balcerzak Stanley Ohio State University Hospital, Columbus, OH, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 105-107 0167-6997 8:1<105 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence SWISSBIB 460423886 BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer